Conference on Biosimilars Congregation 2012

Venue: -

Location: -

Event Date/Time: Feb 24, 2012 End Date/Time: Feb 24, 2012
Report as Spam

Description

Conference on Biosimilars Congregation 2012 to be Held at Hilton London Euston Hotel, London UK on February 24th 2012

Conference Intro:

According to Global Industry Analysts Inc.. the global market for biosimilars is forecast to reach US$4.8 billion by the year 2015. Key factors driving market growth include patent expiries of key biological drugs, cost containment measures from governments, aging population, and supporting legislations. The recent establishment of regulatory guidelines for biosimilars in the US is expected to add further momentum to the growth of the global biosimilars market. http://www.companyprofilesandconferences.com/seminars-conferences/Biosimilars-Congregation-2012.html

The pharmaceutical industry is facing a tough road ahead in the future marketplace. Though pharmaceuticals remain the most cost-effective healthcare intervention, everyone should bring about a significant transformation in their organizations to realize a glorious future. Biosimilars remains to be a provocative subject in the global pharmaceutical industry. However, with the sector promising significant cost savings to the industry, several major markets are welcoming biosimilar legislations for the development of biosimilars. Consequently, biosimilars are expected to grow into a multi-billion dollar market in future

Key themes discussed at this Summit:
Reviewing some of the challenges in clinical study design for biosimilar development arising from endpoint variability, changes in clinical practice, and evolution in understanding of the biology of the disease
How should the pharma and generics industries approach the rapidly emerging and developing biosimilar market? The future of next generation Biosimilars
How are policy makers shaping the contours of this new generic frontier, and what implications they have for current biologic drug development and patent protection?
Identifying issues and solutions surrounding biosimiliars and clinical trials.
Next generation monoclonal antibody development and clinical challenges with biosimilar drug development
Overcoming pricing and reimbursement challenges to maximise the ROI
Determining the right investments & potential returns from Biosimilars
Commercial challenges and opportunities - strategies to develop Biosimilars
Biosimilars Vs Bio-betters – positioning for a new market with lucrative prospects
Learn to implement best practices through recent successful strategies and business models – real time case studies
Analyze the FDA''''''''s current view of biosimilars
The developing regulatory framework in advanced and developing markets
EMA Regulatory Opinions on Treatment of mAbs
Critical issues in demonstrating biosimilarity and maintaining diligent quality control
Be part of a major networking opportunity
For more information kindly visit : http://www.companyprofilesandconferences.com/seminars-conferences/Biosimilars-Congregation-2012.html

Or

Contact us at :

Company Profiles And Conferences
Phone : +91 22 2756 1536
Fax : +91 22 2757 9131
E-mail : info@companyprofilesandconferences.com
Website : www.companyprofilesandconferences.com

Venue

-
-
MORE INFO ON THIS VENUE